Nephrotoxicity of Cancer Treatment in Children

• Campbell J , WallaceWHB, BhattiLAet al.: Trends in incidence, mortality and survival 1975–1999. In: Childhood Cancer in Scotland. NHS Scotland Information and Statistics Division, Edinburgh, UK (2004).
   Google Scholar
• Kroll ME , PassmoreSJ, StillerCAet al.: Childhood cancer - UK. Cancer Res.63–72(2004).
   Google Scholar
• Curry HL , ParkesSE, PowellJEet al.: Caring for survivors of childhood cancers: the size of the problem.Eur. J. Cancer42, 501–508(2006).
   PubMed Web of Science ®Google Scholar
• Stevens MCG , MahlerH, ParkesS: The health status of adult survivors of cancer in childhood.Eur. J. Cancer34, 694–698(1998).
   PubMed Web of Science ®Google Scholar
• Oeffinger KC , MertensAC, SklarCAet al.: Chronic health conditions in adult survivors of childhood cancer.N. Engl. J. Med.355, 1572–1582(2006).
   PubMed Web of Science ®Google Scholar
• Brandt LJ , BroadbentV: Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?Med. Pediatr. Oncol.21, 31–35(1993).
   PubMedGoogle Scholar
• Skinner R , CotterillS, StevensMCGet al.: Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group Study.Br. J. Cancer82, 1636–1645(2000).
   PubMed Web of Science ®Google Scholar
• Hayes FA , GreenAA, CasperJet al.: Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.Cancer48, 1715–1718(1981).
   PubMed Web of Science ®Google Scholar
• Diller L , ChowEJ, GurneyJGet al.: Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.J. Clin. Oncol.27, 2339–2355(2009).
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V , OudardS, JanusNet al.: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study.Cancer110, 1376–1384(2007).
   PubMed Web of Science ®Google Scholar
• Douville P , MartelAR, TalbotJet al.: Impact of age on glomerular filtration estimates.Nephrol. Dial. Transplant.24, 97–103(2009).
   PubMed Web of Science ®Google Scholar
• Lewis MA , ShawJ, SinhaMet al.: Demography of the UK paediatric renal replacement therapy population. In: UK Renal Registry Report 2008. Ansell D, Feest T, Williams A et al. (Eds). UK Renal Registry, Bristol, UK, 257–267(2008).
   Google Scholar
• de Jonge MJA , VerweijJ: Renal toxicities of chemotherapy.Semin. Oncol.33, 68–73(2006).
   PubMed Web of Science ®Google Scholar
• Finkel KW , ForingerJR: Renal disease in patients with cancer.Nat. Clin. Pract. Nephrol.3, 669–678(2007).
   PubMedGoogle Scholar
• Izzedine H , Launay-VacherV, Isnard-BagnisCet al.: Drug-induced Fanconi‘s syndrome.Am. J. Kidney Dis.41, 292–309(2003).
   PubMed Web of Science ®Google Scholar
• Jones DP , SpuntSL, GreenDet al.: Renal late effects in patients treated for cancer in childhood: a report from the Children’s Oncology Group.Pediatr. Blood Cancer51, 724–731(2008).
   PubMed Web of Science ®Google Scholar
• Patzer L : Nephrotoxicity as a cause of acute kidney injury in children.Pediatr. Nephrol.23, 2159–2173(2008).
   PubMedGoogle Scholar
• Sahni V , ChoudhuryD, AhmedZ: Chemotherapy-associated renal dysfunction.Nat. Rev. Nephrol.5, 450–462(2009).
   PubMed Web of Science ®Google Scholar
• Dawson LA , KavanaghBD, PaulinoACet al.: Radiation-associated kidney injury.Int. J. Radiation Oncol. Biol. Phys.76, S108–S115 (2010).
   PubMed Web of Science ®Google Scholar
• Luxton RW : Radiation nephritis.Lancet2, 1221–1224(1961).
   PubMed Web of Science ®Google Scholar
• Donckerwolke RM , CoppesMJ: Adaptation of renal function after unilateral nephrectomy in children with renal tumors.Pediatr. Nephrol.16, 568–574(2001).
   PubMed Web of Science ®Google Scholar
• Welch TR , McAdamsAJ: Focal glomerulosclerosis as a late sequela of Wilms’ tumor.J. Pediatr.108, 105–109(1986).
   PubMed Web of Science ®Google Scholar
• Skinner R : Chronic ifosfamide nephrotoxicity in children.Med. Pediatr. Oncol.41, 190–197(2003).
   PubMedGoogle Scholar
• Heney D , WheeldonJ, RushworthPet al.: Progressive renal toxicity due to ifosfamide.Arch. Dis. Child.66, 966–970(1991).
   PubMed Web of Science ®Google Scholar
• Willemse PHB , de Jong PE, Elema JD et al.: Severe renal failure following high-dose ifosfamide and mesna. Cancer Chemother. Pharmacol.23, 329–330(1989).
   PubMed Web of Science ®Google Scholar
• Prasad VK , LewisIJ, AparicioSRet al.: Progressive glomerular toxicity of ifosfamide in children.Med. Pediatr. Oncol.27, 149–155(1996).
   PubMedGoogle Scholar
• Skinner R , PearsonADJ, CoulthardMGet al.: Assessment of chemotherapy-associated nephrotoxicity in children with cancer.Cancer Chemother. Pharmacol.28, 81–92(1991).
   PubMed Web of Science ®Google Scholar
• Pratt CB , MeyerWH, JenkinsJJet al.: Ifosfamide, Fanconi‘s syndrome, and rickets.J. Clin. Oncol.9, 1495–1499(1991).
   PubMed Web of Science ®Google Scholar
• De Schepper J , Hachimi-IdrissiS, VerbovenMet al.: Renal function abnormalities after ifosfamide treatment in children.Acta. Paediatr.82, 373–376(1993).
   PubMed Web of Science ®Google Scholar
• Skinner R , PearsonADJ, EnglishMWet al.: Risk factors for ifosfamide nephrotoxicity in children.Lancet348, 578–580(1996).
   PubMed Web of Science ®Google Scholar
• Stohr W , PaulidesM, BielackSet al.: Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance system.Pediatr. Blood Cancer48, 447–452(2007).
   PubMed Web of Science ®Google Scholar
• Al Sheyyab M , WorthingtonD, BeethamRet al.: The assessment of subclinical ifosfamide-induced renal tubular toxicity using urinary excretion of retinol-binding protein.Pediatr. Hematol. Oncol.10, 119–128(1993).
   PubMed Web of Science ®Google Scholar
• Goren MP , WrightRK, HorowitzMEet al.: Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein.Am. J. Clin. Pathol.86, 780–783(1986).
   PubMed Web of Science ®Google Scholar
• Skinner R , SharkeyIM, PearsonADJet al.: Ifosfamide, mesna and nephrotoxicity in children.J. Clin. Oncol.11, 173–190(1993).
   PubMed Web of Science ®Google Scholar
• Ashraf MS , BradyJ, BreatnachFet al.: Ifosfamide nephrotoxicity in paediatric cancer patients.Eur. J. Paediatr.153, 90–94(1994).
   PubMed Web of Science ®Google Scholar
• Friedlaender MM , HavivYS, RosenmannEet al.: End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy.Am. J. Nephrol.18, 131–133(1998).
   PubMed Web of Science ®Google Scholar
• Loebstein R : Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.J. Clin. Pharmacol.39, 454–461(1999).
   PubMed Web of Science ®Google Scholar
• Rossi R , GoddeA, KleinebrandAet al.: Concentrating capacity in ifosfamide-induced severe renal dysfunction.Ren. Fail.17, 551–557(1995).
   PubMed Web of Science ®Google Scholar
• Goren MP , PrattCB, ViarMJ: Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.Cancer Chemother. Pharmacol.25, 70–72(1989).
   PubMed Web of Science ®Google Scholar
• MacLean FR , SkinnerR, HallAGet al.: Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.Cancer Chemother. Pharmacol.41, 413–416(1998).
   PubMed Web of Science ®Google Scholar
• Mundel P , ReiserJ: Proteinuria: an enzymatic disease of the podocyte?Kidney Int.77, 571–580(2010).
   PubMed Web of Science ®Google Scholar
• Nielsen R , ChristensenEI: Proteinuria and events beyond the slit.Pediatr. Nephrol.25, 813–822(2010).
   PubMed Web of Science ®Google Scholar
• Burk CD , RestainoI, KaplanBSet al.: Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor.J. Pediatr.117, 331–335(1990).
   PubMed Web of Science ®Google Scholar
• Stohr W , PatzerL, PaulidesMet al.: Growth impairment after ifosfamide-induced nephrotoxicity in children.Pediatr. Blood Cancer48, 571–576(2007).
   PubMed Web of Science ®Google Scholar
• Caron HN , AbelingN, van Gennip A et al.: Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med. Pediatr. Oncol.20, 42–47(1992).
   PubMedGoogle Scholar
• Van Gool S , BrockP, WijndaeleGet al.: Reversible hypophosphatemic rickets following ifosfamide treatment.Med. Pediatr. Oncol.20, 254–257(1992).
   PubMedGoogle Scholar
• Ashraf MS , SkinnerR, EnglishMWet al.: Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child.Med. Pediatr. Oncol.28, 62–64(1997).
   PubMedGoogle Scholar
• Skinner R , ParryA, PriceLet al.: Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.Pediatr. Blood Cancer54, 983–989(2010).
   PubMed Web of Science ®Google Scholar
• Oberlin O , FawazO, ReyAet al.: Long-term evaluation of ifosfamide-related nephrotoxicity in children.J. Clin. Oncol.27, 5350–5355(2009).
   PubMed Web of Science ®Google Scholar
• Raney B , EnsignLG, ForemanJet al.: Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual disease.Am. J. Pediatr. Hematol. Oncol.16, 286–295(1994).
   PubMedGoogle Scholar
• Shore R , GreenbergM, GearyDet al.: Iphosphamide-induced nephrotoxicity in children.Pediatr. Nephrol.6, 162–165(1992).
   PubMed Web of Science ®Google Scholar
• Rossi R , GoddeA, KleinebrandAet al.: Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.J. Clin. Oncol.12, 159–165(1994).
   PubMed Web of Science ®Google Scholar
• Skinner R , ParryA, PriceLet al.: Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.Pediatr. Blood Cancer54(7), 983–989(2010).
   PubMed Web of Science ®Google Scholar
• Boddy AV , EnglishMW, PearsonADJet al.: Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.Eur. J. Cancer32A, 1179–1184(1996).
   PubMed Web of Science ®Google Scholar
• Rossi R , SchafersP, PleyerJet al.: The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment.Int. J. Pediatr. Hematol. Oncol.4, 393–399(1997).
   Web of Science ®Google Scholar
• Elias AD , AyashLJ, EderJPet al.: A Phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.J. Clin. Oncol.9, 320–327(1991).
   PubMed Web of Science ®Google Scholar
• Hanly L , ChenN, RiederMet al.: Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.Expert Opin Drug Saf.8, 155–168(2009).
   PubMed Web of Science ®Google Scholar
• Hill PA , PrinceHM, PowerDA: Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.Pathology32, 166–170(2000).
   PubMed Web of Science ®Google Scholar
• Morland BJ , MannJR, MilfordDVet al.: Ifosfamide nephrotoxicity in children: histopathological features in two cases.Med. Pediatr. Oncol.27, 57–61(1996).
   PubMedGoogle Scholar
• Broadhead CL , WalkerD, SkinnerRet al.: Differential cytotoxicity of ifosfamide and its metabolites in renal epithelial cell cultures.Toxicol. in vitro12, 209–217(1998).
   PubMed Web of Science ®Google Scholar
• Mohrmann M , AnsorgeS, SchmichUet al.: Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.Pediatr. Nephrol.8, 157–163(1994).
   PubMed Web of Science ®Google Scholar
• Nissim I , WeinbergJM: Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats.Kidney Int.49, 684–695(1996).
   PubMed Web of Science ®Google Scholar
• Rossi R : Nephrotoxicity of ifosfamide – moving towards understanding the molecular mechanisms.Nephrol. Dial. Transplant12, 1091–1092(1997).
   PubMed Web of Science ®Google Scholar
• Silies H , BlaschkeG, HohenlochterBet al.: Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.Int. J. Clin. Pharmacol. Ther.36, 246–252(1998).
   PubMed Web of Science ®Google Scholar
• Tasso MJ , BoddyAV, PriceLet al.: Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.Cancer Chemother. Pharmacol.30, 207–211(1992).
   PubMed Web of Science ®Google Scholar
• Mohrmann M , PauliA, WalkenhorstHet al.: Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture.Renal Physiol. Biochem.16, 285–298(1993).
   PubMedGoogle Scholar
• Zamlauski-Tucker MJ , MorrisME, SpringateJE: Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney.Toxicol. Appl. Pharmacol.129, 170–175(1994).
   PubMed Web of Science ®Google Scholar
• McCune JS , RislerLJ, PhillipsBRet al.: Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechlorethylation.Drug Metab. Dispos.33, 1074–1081(2005).
   PubMed Web of Science ®Google Scholar
• Mohrmann M , AnsorgeS, SchonfeldBet al.: Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.Pediatr. Nephrol.8, 458–465(1994).
   PubMed Web of Science ®Google Scholar
• Skinner R , ParryA, PriceLet al.: Persistent nephrotoxicity during ten year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.Eur. J. Cancer45, 3213–3219(2009).
   PubMed Web of Science ®Google Scholar
• Kamalaker P , FreemanAI, HigbyDJet al.: Clinical response and toxicity with cis-dichlorodiammine-platinum (II) in children.Cancer Treat Rep.61, 835–839(1977).
   PubMedGoogle Scholar
• Stohr W , PaulidesM, BielackSet al.: Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.Pediatr. Blood Cancer48, 140–147(2007).
   PubMed Web of Science ®Google Scholar
• Womer RB , PritchardJ, BarrattTM: Renal toxicity of cisplatin in children.J. Pediatr.106, 659–663(1985).
   PubMed Web of Science ®Google Scholar
• Brock PR , KoliouskasDE, BarrattTMet al.: Partial reversibility of cisplatin nephrotoxicity in children.J. Pediatr.118, 531–534(1991).
   PubMed Web of Science ®Google Scholar
• Hartmann O , PinkertonCR, PhilipTet al.: Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma.J. Clin. Oncol.6, 44–50(1988).
   PubMed Web of Science ®Google Scholar
• Pratt CB , HayesA, GreenAAet al.: Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a Phase II study.Cancer Treat Rep.65, 1021–1026(1981).
   PubMedGoogle Scholar
• Madias NE , HarringtonJT: Platinum nephrotoxicity.Am. J. Med.65, 307–314(1978).
   PubMed Web of Science ®Google Scholar
• Daugaard G , RossingN, RorthM: Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.Cancer Chemother. Pharmacol.21, 163–167(1988).
   PubMed Web of Science ®Google Scholar
• Lam M , AdelsteinDJ: Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin.Am. J. Kidney Dis.8, 164–169(1986).
   PubMed Web of Science ®Google Scholar
• Bianchetti MG , KanakaC, Ridolfi-LuthyAet al.: Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin.Pediatr. Nephrol.4, 219–222(1990).
   PubMed Web of Science ®Google Scholar
• Daugaard G , AbildgaardU, Holsten-RathlouNHet al.: Renal tubular function in patients treated with high-dose cisplatin.Clin. Pharmacol. Ther.44, 164–172(1988).
   PubMed Web of Science ®Google Scholar
• Bellin SL , SelimM: Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature.Gynecol. Oncol.30, 104–113(1988).
   PubMed Web of Science ®Google Scholar
• Rude RK , OldhamSB, SingerFR: Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency.Clin. Endocrinol.5, 209–224(1976).
   PubMed Web of Science ®Google Scholar
• Daugaard G , AbildgaardU: Cisplatin nephrotoxicity.Cancer Chemother. Pharmacol.25, 1–9(1989).
   PubMed Web of Science ®Google Scholar
• Kurtzberg J , DennisVW, KinneyTR: Cisplatinum-induced renal salt wasting.Med. Pediatr. Oncol.12, 150–154(1984).
   PubMedGoogle Scholar
• Wong NLM , WalkerVR, WongEFCet al.: Mechanism of polyuria after cisplatin therapy.Nephron65, 623–627(1993).
   PubMed Web of Science ®Google Scholar
• Verplanke AJW , HerberRFM, de Wit R et al.: Comparison of renal function parameters in the assessment of cisplatin induced nephrotoxicity. Nephron66, 267–272(1994).
   PubMed Web of Science ®Google Scholar
• Ettinger LJ , DouglassHO, HigbyDJet al.: Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma.Cancer47, 248–254. (1981).
   PubMed Web of Science ®Google Scholar
• Harrell RM , SibleyR, VogelzangNJ: Renal vascular lesions after chemotherapy with vinblastine, bleomycin and cisplatin.Am. J. Med.23, 429–433(1982).
   Google Scholar
• Canpolat C , PearsonP, JaffeN: Cisplatin-associated hemolytic uremic syndrome.Cancer74, 3059–3062(1994).
   PubMed Web of Science ®Google Scholar
• Skinner R , PearsonADJ, EnglishMWet al.: Cisplatin dose rate as a risk factor for nephrotoxicity in children.Br. J. Cancer81, 336–341(1998).
   Google Scholar
• Preiss R , BrovtsynVK, PerevodchikovaNIet al.: Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin.Eur. J. Clin. Pharmacol.34, 139–144(1988).
   PubMed Web of Science ®Google Scholar
• Reece PA , StaffordI, RussellJet al.: Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.J. Clin. Oncol.5, 304–309(1987).
   PubMed Web of Science ®Google Scholar
• Gietema JA , MeinardiMT, MesserschmidtJet al.: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer (letter).Lancet355, 1075–1076(2000).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Vitale JC , HayesDM, CvitkovicEet al.: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride.Cancer39, 1362–1371(1977).
   PubMed Web of Science ®Google Scholar
• Arany I , SafirsteinRL: Cisplatin nephrotoxicity.Semin. Nephrol.23, 460–464(2003).
   PubMed Web of Science ®Google Scholar
• Yao X , PanichpisalK, KurtzmanNet al.: Cisplatin nephrotoxicity: a review.Am. J. Med. Sci334, 115–124(2007).
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT , McBrienDCH: The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity.Biochem. Pharmacol.34, 1423–1428(1985).
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT , McBrienDCH: Enhancement of cisplatin nephrotoxicity by probenecid (letter).Cancer Treat. Rep.68, 445–446(1984).
   PubMedGoogle Scholar
• Caterson R , EtheredgeS, SnitchPet al.: Mechanisms of renal excretion of cisdichlorodiamine platinum.Res. Commun. Chem. Pathol. Pharmacol.41, 255–264(1983).
   PubMedGoogle Scholar
• Williams PD , HottendorfGH: Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex.Cancer Treat. Rep.69, 875–880(1985).
   PubMedGoogle Scholar
• Barros EJG , BoimMA, SantosOFPet al.: Effect of cisplatin on glomerular haemodynamics.Braz. J. Med. Biol. Res.22, 1295–1301(1989).
   PubMed Web of Science ®Google Scholar
• Blochl-Daum B , PehambergerH, KurzCet al.: Effects of cisplatin on urinary thromboxane B2 excretion.Clin. Pharmacol. Ther.58, 418–424(1995).
   PubMed Web of Science ®Google Scholar
• dos Santos OFP , BoimMA, BarrosEJGet al.: Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin.Lipids26, 1324–1328(1991).
   PubMed Web of Science ®Google Scholar
• Heidemann HT , MullerS, MertinsLet al.: Effect of aminophylline on cisplatin nephrotoxicity in the rat.Br. J. Pharmacol.97, 313–318(1989).
   PubMed Web of Science ®Google Scholar
• Singh G : A possible cellular mechanism of cisplatin-induced nephrotoxicity.Toxicology58, 71–80(1989).
   PubMed Web of Science ®Google Scholar
• Zhang JG , LindupWE: Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices.Biochem. Pharmacol.47, 1127–1135(1994).
   PubMed Web of Science ®Google Scholar
• Doz F , PinkertonR: What is the place of carboplatin in paediatric oncology?Eur. J. Cancer30A, 194–201(1994).
   PubMed Web of Science ®Google Scholar
• Calvert AH , HarlandSJ, NewellDRet al.: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother. Pharmacol.9, 140–147(1982).
   PubMed Web of Science ®Google Scholar
• Foster BJ , Clagett-CarrK, Leyland-JonesBet al.: Results of NCI-sponsored Phase I trials with carboplatin.Cancer Treat Rev.12(Suppl A), 43–49(1985).
   PubMed Web of Science ®Google Scholar
• Bergeron C , DubourgL, ChastagnerPet al.: Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study.Pediatr. Blood Cancer45, 32–36(2005).
   PubMed Web of Science ®Google Scholar
• Pinkerton CR , BroadbentV, HorwichAet al.: JEB – a carboplatin based regimen for malignant germ cell tumours in children.Br. J. Cancer62, 257–262(1990).
   PubMed Web of Science ®Google Scholar
• Lewis IJ , StevensMCG, PearsonADJet al.: Carboplatin activity in cisplatin treated neuroblastoma.Adv. Neuroblastoma Res.3, 553–559(1991).
   Google Scholar
• Ettinger LJ , SiegelSE, BaumESet al.: Phase I pediatric trial of cis-diammine-1, 1-cyclobutane dicarboxylate platinum II (NSC 241240, CBDCA) (abstract).Am. Soc. Clin. Oncol. Abstracts1, 44 (1984).
   Google Scholar
• Curt GA , GrygielJJ, CordenBJet al.: A Phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylato-platinum (NSC 241240).Cancer Res.43, 4470–4473(1983).
   PubMedGoogle Scholar
• McDonald BR , KirmaniS, VasquezMet al.: Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature.Am. J. Med.90, 386–391(1991).
   PubMed Web of Science ®Google Scholar
• Shea TC , FlahertyM, EliasAet al.: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.J. Clin. Oncol.7, 651–661(1989).
   PubMed Web of Science ®Google Scholar
• Frenkel J , KoolG, de Kraker J: Acute renal failure in high dose carboplatin chemotherapy. Med. Pediatr. Oncol.25, 473–474(1995).
   PubMedGoogle Scholar
• Gordon SJ , PearsonADJ, ReidMMet al.: Toxicity of single-day high-dose vincristine, melphalan, etoposide, and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma.Eur. J. Cancer28A, 1319–1323(1992).
   PubMed Web of Science ®Google Scholar
• English MW , SkinnerR, PearsonADJet al.: Dose-related nephrotoxicity of carboplatin in children.Br. J. Cancer81, 336–341(1999).
   PubMed Web of Science ®Google Scholar
• Tscherning C , RubieH, ChancholleAet al.: Recurrent renal salt wasting in a child treated with carboplatin and etoposide.Cancer73, 1761–1763(1994).
   PubMed Web of Science ®Google Scholar
• Butani L , WestDC, TaylorDS: End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation.Pediatr. Transplant.7, 408–412(2003).
   PubMed Web of Science ®Google Scholar
• Siddik ZH , DibleSE, BoxallFEet al. Renal pharmacokinetics and toxicity of cisplatin and carboplatin in animals. In: Biochemical Mechanisms of Platinum Antitumour Drugs. McBrien DCH, Slater TF (Eds). IRL Press Ltd, Oxford, UK, 171–198(1986).
   Google Scholar
• Von Hoff DD , PentaJS, HelmanLJet al.: Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.Cancer Treat Rep.61, 745–748(1977).
   PubMedGoogle Scholar
• Abelson HT , FosburgMT, BeardsleyGPet al.: Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.J. Clin. Oncol.1, 208–216(1983).
   PubMed Web of Science ®Google Scholar
• Turello R , RentschK, Di Paolo E et al.: Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism. Pediatr. Blood Cancer50, 154–156(2007).
   Web of Science ®Google Scholar
• Weiss RB , PosadaJG Jr, Kramer RA et al.: Nephrotoxicity of semustine. Cancer Treat Rep.67, 1105–1112(1983).
   PubMedGoogle Scholar
• Micetich KC , Jensen-AkulaM, MandardJCet al.: Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.Am. J. Med.71, 967–972(1981).
   PubMed Web of Science ®Google Scholar
• Harman WE , CohenHJ, SchneebergerEEet al.: Chronic renal failure in children treated with methyl CCNU.N. Engl. J. Med.300, 1200–1203(1979).
   PubMed Web of Science ®Google Scholar
• Schacht RG , FeinerHD, GalloGRet al.: Nephrotoxicity of nitrosoureas.Cancer48, 1328–1334(1981).
   PubMed Web of Science ®Google Scholar
• Silver HKB , MortonDL: CCNU nephrotoxicity following sustained remission in oat cell carcinoma.Cancer Treat. Rep.63, 226–227(1979).
   PubMedGoogle Scholar
• Sadoff L : Nephrotoxicity of streptozotocin (NSC-85998).Cancer Chemother. Rep.54, 457–459(1970).
   PubMedGoogle Scholar
• Schein PS , O‘ConnellMJ, BlomJet al.: Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).Cancer34, 993–1000(1974).
   PubMed Web of Science ®Google Scholar
• McElwain TJ , HedleyDW, BurtonGet al.: Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.Br. J. Cancer40, 72–80(1979).
   PubMed Web of Science ®Google Scholar
• Helenglass G , PowlesRL, McElwainTJet al.: Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.Bone Marrow Transplant3, 21–29(1988).
   PubMed Web of Science ®Google Scholar
• Devine SM , SanbornR, JessopEet al.: Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.Bone Marrow Transplant28, 557–562(2001).
   PubMed Web of Science ®Google Scholar
• Alix JL , SwierczP, SchaererRet al.: Nephrotoxicite du melphalan utilise a haute dose.Presse Med.12, 575–576(1983).
   PubMedGoogle Scholar
• Leung N , SlezakJM, BergstralhEJet al.: Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.Am. J. Kidney Dis.45, 102–111(2005).
   PubMed Web of Science ®Google Scholar
• Arneil GC , EmmanuelIG, FlatmanGEet al.: Nephritis in two children after irradiation and chemotherapy for nephroblastoma.Lancet1, 960–963(1974).
   PubMed Web of Science ®Google Scholar
• Makipernaa A , KoskimiesO, JaaskelainenJet al.: Renal growth and function 11–28 years after treatment of Wilms’ tumour.Eur. J. Pediatr.150, 444–447(1991).
   PubMed Web of Science ®Google Scholar
• Lopes VM : Cyclophosphamide nephrotoxicity in man (letter).Lancet1, 1060 (1967).
   Web of Science ®Google Scholar
• Harlow PJ , DeClerckYA, ShoreNAet al.: A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy.Cancer44, 896–898(1979).
   PubMed Web of Science ®Google Scholar
• Slavin RE , DiasMA, SaralR: Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. A clinico-pathologic study of 33 patients.Cancer42, 1747–1759(1978).
   PubMed Web of Science ®Google Scholar
• Bardi E , BobokI, OlahAVet al.: Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.Pathol. Oncol. Res.13, 249–253(2007).
   PubMed Web of Science ®Google Scholar
• Burke JF , LauciusJF, BrodovskyHSet al.: Doxorubicin hydrochloride-associated renal failure.Arch. Intern. Med.137, 385–388(1977).
   PubMedGoogle Scholar
• Presant CA , DenesAE, KleinLet al.: Phase I and preliminary Phase II observations of high-dose intermittent 6-thioguanine.Cancer Treat Rep.64, 1109–1113(1980).
   PubMedGoogle Scholar
• Stuart MJ , CuasoC, MillerMet al.: Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine.Blood45, 315–320(1975).
   PubMed Web of Science ®Google Scholar
• Peterson BA , CollinsAJ, VogelzangNJet al.: 5-azacytidine and renal tubular dysfunction.Blood57, 182–185(1981).
   PubMed Web of Science ®Google Scholar
• Kennedy BJ : Metabolic and toxic effects of mithramycin during tumor therapy.Am. J. Med.49, 494–503(1970).
   PubMed Web of Science ®Google Scholar
• Hanna WT , KraussS, RegesterRFet al.: Renal disease after mitomycin C therapy.Cancer48, 2583–2588(1981).
   PubMed Web of Science ®Google Scholar
• Lesesne JB , RothschildN, EricksonBet al.: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.J. Clin. Oncol.7, 781–789(1989).
   PubMed Web of Science ®Google Scholar
• Fung MC , StornioloAM, NguyenBet al.: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.Cancer85, 2023–2032(1999).
   PubMed Web of Science ®Google Scholar
• Batts ED , LazarusHM: Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?Bone Marrow Transplant40, 709–719(2007).
   PubMed Web of Science ®Google Scholar
• Nair S , ErnstoffMS, BahnsonRRet al.: Interferon-induced reversible acute renal failure with nephrotic syndrome.Urology39, 169–172(1992).
   PubMed Web of Science ®Google Scholar
• Geertsen PF , von der Maase H, Olsen NV, Fogh-Andersen N, Nielsen SL, Leyssac PP: Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2. Clin. Sci. (Lond.)95, 73–81(1998).
   PubMed Web of Science ®Google Scholar
• Margolis J , GreverMR: Pentostatin (Nipent): a review of potential toxicity and its management.Semin. Oncol.27(Suppl. 5), 9–14(2000).
   PubMed Web of Science ®Google Scholar
• Fakih M : Anti-EGFR monoclonal antibody-induced hypomagnesaemia.Lancet Oncol.8, 366–367(2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , PeetersM, SienaSet al.: Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.J. Clin. Oncol.25, 1658–1664(2007).
   PubMed Web of Science ®Google Scholar
• Zhu X , WuS, DahutWet al.: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and metaanalysis.Am. J. Kidney Dis.49, 186–193(2007).
   PubMed Web of Science ®Google Scholar
• Bailey S , RobertsA, BrockCet al.: Nephrotoxicity in survivors of Wilms’ tumours in the north of England.Br. J. Cancer87, 1092–1098(2002).
   PubMed Web of Science ®Google Scholar
• Wikstad I , CelsiG, LarssonLet al.: Kidney function in adults born with unilateral agenesis or nephrectomized in childhood.Pediatr. Nephrol.2, 177–182(1988).
   PubMed Web of Science ®Google Scholar
• Levitt GA , YeomansE, Dicks Mireaux C et al.: Renal size and function after cure of Wilms’ tumour. Br. J. Cancer66, 877–882(1992).
   PubMed Web of Science ®Google Scholar
• Finkelstein JZ , NorkoolP, GreenDMet al.: Diastolic hypertension in Wilms tumour survivors: a late effect of treatment.Am. J. Clin. Oncol.16, 201–205(1993).
   PubMed Web of Science ®Google Scholar
• Cohen EP , RobbinsME: Radiation nephropathy.Semin. Nephrol.23, 486–499(2003).
   PubMed Web of Science ®Google Scholar
• Cruz DN , PerazellaMA, MahnensmithRL: Bone marrow transplant nephropathy: a case report and review of the literature.J. Am. Soc. Nephrol.8, 166–173(1997).
   PubMed Web of Science ®Google Scholar
• Patzer L , RingelmannF, KentoucheK: Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial.Bone Marrow Transplant27, 319–327(2001).
   PubMed Web of Science ®Google Scholar
• Esiashvili N , ChiangKY, HasselleMDet al.: Renal toxicity in children undergoing total body irradiation for bone marrow transplant.Radiother. Oncol.90, 242–246(2009).
   PubMed Web of Science ®Google Scholar
• Kist-van Holthe JE , van Zwet JM, Brand R et al.: Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant1998, 559–564(1998).
   Google Scholar
• Andersen TB , Eskild-JensenA, Fr⊘kiærJet al.: Measuring glomerular filtration rate in children: can cystatin C replace established methods? A review.Pediatr. Nephrol.24, 929–941(2009).
   PubMed Web of Science ®Google Scholar
• Skinner R , ColeM, PearsonADJet al.: Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio.Arch. Dis. Child.70, 387–390(1994).
   PubMed Web of Science ®Google Scholar
• Icli F , KaraoguzH, DincolDet al.: Severe vascular toxicity associated with cisplatin-based chemotherapy.Cancer72, 587–593(1993).
   PubMed Web of Science ®Google Scholar
• Thomas H , BoddyAV, EnglishMWet al.: Prospective validation of renal function–based carboplatin dosing in children with cancer: a United Kingdom Children’s Cancer Study Group Trial.J. Clin. Oncol.18, 3614–3621(2000).
   PubMed Web of Science ®Google Scholar
• Kintzel PE , DorrRT: Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.Cancer Treat. Rev.21, 33–64(1995).
   PubMed Web of Science ®Google Scholar
• Loebstein R , KorenG: Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.Pediatr.101, e8 (1998).
   PubMed Web of Science ®Google Scholar
• Aleksa K , HalachmiN, ItoSet al.: A tubule cell model for ifosfamide nephrotoxicity.Can. J. Physiol. Pharmacol.83, 499–508(2005).
   PubMed Web of Science ®Google Scholar
• Sener G , SehirliO, YegenBCet al.: Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats.J. Pineal. Res.37, 17–25(2004).
   PubMed Web of Science ®Google Scholar
• Chen N , AleksaK, WoodlandCet al.: The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells.Transl. Res.150, 51–57(2007).
   PubMed Web of Science ®Google Scholar
• Schlenzig JS , CharpentierC, RabierDet al.: l-carnitine: a way to decrease cellular toxicity of ifosfamide? (letter).Eur. J. Pediatr.154, 686–690(1995).
   PubMed Web of Science ®Google Scholar
• Cornelison TL , ReedE: Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol. Oncol.50, 147–158(1993).
   PubMed Web of Science ®Google Scholar
• Pinzani V , BressolleF, HaugIJet al.: Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.Cancer Chemother. Pharmacol.35, 1–9(1994).
   PubMed Web of Science ®Google Scholar
• Reed E , JacobJ: Carboplatin and renal dysfunction (letter).Ann. Intern. Med.110, 409 (1989).
   PubMed Web of Science ®Google Scholar
• Kibirige MS , Morris Jones PH, Addison GM: Prevention of cisplatin-induced hypomagnesemia. Pediatr. Hematol. Oncol.5, 1–6(1988).
   PubMed Web of Science ®Google Scholar
• Jones MM , BasingerMA, HolscherMA: Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds.Fundam. Appl. Toxicol.18, 181–188(1992).
   PubMedGoogle Scholar
• Fouladi M , ChintagumpalaM, AshleyDet al.: Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.J. Clin. Oncol.26, 3749–3755(2008).
   PubMed Web of Science ®Google Scholar
• Hensley ML , HagertyKL, KewalramaniTet al.: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.J. Clin. Oncol.27, 127–145(2009).
   PubMed Web of Science ®Google Scholar
• Hayek M : Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.Pediatr. Hematol. Oncol.20, 253–256(2003).
   PubMed Web of Science ®Google Scholar
• Katzenstein HM , ChangKW, KrailoMet al.: Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma.Cancer115, 5828–5835(2009).
   PubMed Web of Science ®Google Scholar
• Imai T , FujiiK, ShiraishiSet al.: Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates.J. Pharm. Sci.86, 244–247(1997).
   PubMed Web of Science ®Google Scholar
• Veal GJ , GriffinMJ, PriceEet al.: A Phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.Br. J. Cancer84, 1029–1035(2001).
   PubMed Web of Science ®Google Scholar
• Esposito M , VialeM, VannozziMOet al.: Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II).Toxicol. Appl. Pharmacol.140, 370–377(1996).
   PubMed Web of Science ®Google Scholar
• Jacobs C , KaubischS, HalseyJet al.: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity.Cancer67, 1518–1524(1991).
   PubMed Web of Science ®Google Scholar
• Sleijfer DT , OffermanJJG, MulderNHet al.: The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man.Cancer60, 2823–2828(1987).
   PubMed Web of Science ®Google Scholar

Websites

• Piepsz A, Colarinha P, Gordon I et al.: Guidelines for glomerular filtration rate determination in children. EANM Guidelines 2000 www.eanm.org/scientific_info/guidelines/gl_paed_gfrd.pdf (Accessed 14July2010
   Google Scholar
• Children’s Oncology Group: Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers www.survivorshipguidelines.org (Accessed 14July2010)
   Google Scholar
• Skinner R, Wallace WHB, Levitt GA: Therapy based long term follow up: practice statement. UK Childrens Cancer Study Group (Late Effects Group) www.ukccsg.org.uk/public/followup/PracticeStatement/index.html (Accessed 14July2010)
   Google Scholar